Evidence map›Paper›PMID 35596224›Full record

ArticleBMC cancer2022

Berberine inhibits intestinal carcinogenesis by suppressing intestinal pro-inflammatory genes and oncogenic factors through modulating gut microbiota.

Haitao Chen, Chenxiao Ye, Biyu Cai, Fan Zhang, Xuanying Wang, Jin Zhang, Zewei Zhang, Yong Guo, Qinghua Yao

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
9.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Haitao Chen *Department of Integrated Chinese and Western Medicine, Institute of Basic Medicine and Cancer (IBMC), The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Chinese Academy of Sciences, 310022, Hangzhou, Zhejiang, China.
Chenxiao Ye *Zhejiang Chinese Medical University, 310053, Hangzhou, Zhejiang, China.
Biyu CaiZhejiang Chinese Medical University, 310053, Hangzhou, Zhejiang, China.
Fan ZhangZhejiang Chinese Medical University, 310053, Hangzhou, Zhejiang, China.
Xuanying WangZhejiang Chinese Medical University, 310053, Hangzhou, Zhejiang, China.
Jin ZhangZhejiang Chinese Medical University, 310053, Hangzhou, Zhejiang, China.
Zewei ZhangDepartment of Abdominal Surgical Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), 310022, Hangzhou, Zhejiang, China.
Yong GuoDepartment of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University, 310003, Hangzhou, Zhejiang, China. guoyong1047@zcmu.edu.cn.
Qinghua YaoDepartment of Integrated Chinese and Western Medicine, Institute of Basic Medicine and Cancer (IBMC), The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Chinese Academy of Sciences, 310022, Hangzhou, Zhejiang, China. yaoqh@zjcc.org.cn.
Zhejiang Chinese Medical University · CNZhejiang Cancer Hospital · CN

Funding

Medical and Health Platform Program of Zhejiang Province 2021KY569National Natural Science Foundation of China 82074201Natural Science Foundation of Zhejiang Province LY21H290001Natural Science Foundation of Zhejiang Province Z20H290002Zhejiang Provincial Project for the key discipline of Traditional Chinese Medicine 2017-XK-A09
6 · The paper itself

Abstract

backgroundThe role of Berberine (BBR) in colorectal cancer (CRC) and gut microbiota has begun to appreciate. However, there was no direct evidence confirm that the gut microbiota regulated by BBR could inhibit CRC. This report investigated the effect of stool from BBR treated subjects and its effect on CRC.

methodsA mouse model for CRC was developed using azoxymethane (AOM) and dextran sulfate sodium (DSS). Intestinal tissue from affected mice were used to determine the efficacy of BBR against CRC. Stool samples were collected for the 16s rRNA gene sequencing and fecal microbiota transplantation (FMT). Finally, the mechanism of gut microbiota from BBR treated mice on CRC was explored using immunohistochemistry, RNA-Sequencing, quantitative RT-PCR, and western blot analyses.

resultsBBR significantly reduced intestinal tumor development. The richness of gut microbiota were notably decreased by BBR. Specifically, the relative abundance of beneficial bacteria (Roseburia, Eubacterium, Ruminococcaceae, and Firmicutes_unclassified) was increased while the level of bacteria (Odoribacter, Muribaculum, Mucispirillum, and Parasutterella) was decreased by BBR treatment. FMT experiment determined that the mice fed with stool from BBR treated AOM/DSS mice demonstrated a relatively lower abundance of macroscopic polyps and a significantly lower expression of β-catenin, and PCNA in intestinal tissue than mice fed with stool from AOM/DSS mice. Mechanistically, intestinal tissue obtained from mice fed with stool from BBR treated AOM/DSS mice demonstrated a decreased expression of inflammatory cytokines including interleukin 1β (IL-1β), tumor necrosis factor-α (TNF-α), C-C motif chemokine 1 (Ccl1), Ccl6, and C-X-C motif ligand (Cxcl9). In addition, the NF-κB expression was greatly suppressed in mice fed with stool from BBR treated AOM/DSS mice. Real-time PCR arrays revealed a down-regulation of genes involved in cell proliferation, angiogenesis, invasiveness, and metastasis in mice fed with stool from BBR treated AOM/DSS mice.

conclusionsStool obtained from BBR treated AOM/DSS mice was able to increase colon length while simultaneously decreasing the density of macroscopic polyps, cell proliferation, inflammatory modulators and the expression of NF-κB. Therefore, it was concluded that suppression of pro-inflammatory genes and carcinogens factors by modulating gut microbiota was an important pathway for BBR to inhibit tumor growth in conventional mice.

Indexed as

BerberineColitisGastrointestinal MicrobiomeAnimalsAzoxymethaneCarcinogenesisColonDextran SulfateDisease Models, AnimalHumansMiceMice, Inbred C57BLNF-kappa BRNA, Ribosomal, 16SAzoxymethaneBerberineDextran SulfateNF-kappa BRNA, Ribosomal, 16SBerberineColorectal cancerCytokinesFecal microbiota transplantationGut microbiotaMolecular mechanismNF-κB signaling pathway

Identifiers

PMID35596224
PMCPMC9123795
OpenAlexW4281260033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.